Posted by Michael Wonder on 13 Nov 2017
Sarepta gets a belated, but helpful, boost from Anthem for its pricey drug
10 November 2017 - In a boost for Sarepta Therapeutics, the last remaining large health insurer has agreed to cover its pricey treatment for a rare form of muscular dystrophy.
In a policy bulletin issued on Thursday, Anthem declared Exondys 51 to be “medically necessary,” reversing a decision made a year ago not to reimburse the drug, which had just been approved to treat Duchenne muscular dystrophy amid controversy about underlying clinical data.
